Civica Rx and the Blue Cross Blue Shield Association and 18 of its health plans have teamed up to create a new subsidiary that will target low-cost generic drugs.

One-third of healthcare administrative spending could be automated and save $13.3 billion, according to a report by CAQH.

Centene has passed all regulatory hurdles to seal the deal on a merger with WellCare Health Plans worth $17.3 billion.

Amazon is signaling it may soon sell prescription drugs in the U.K., Canada and Australia after the company moved to trademark “Amazon Pharmacy” in those countries at the start of 2020, CNBC reported.

More accountable care organizations are taking on downside financial risk in the Medicare Shared Savings Program than ever before, with 37% in the program today participating in these arrangements.

The world could soon have a new most expensive drug if an experimental gene therapy for hemophilia patients could come in with a price tag between $2 million and $3 million is approved.

The Centers for Medicare & Medicaid Innovation savings projections keep moving, underscoring just how difficult it is to estimate the impact of untested alternative payment models, according to a recent analysis from Avalere Health.

Changing models across hospitals and health systems helped drive mergers and acquisition activity in 2019, according to a new report from Kaufman Hall.

The innovation and venture capital arm of University of Pittsburgh Medical Center (UPMC) is planning to invest $1 billion into life sciences to develop new drugs, diagnostics and devices over the next four years.

Executives in the healthcare space are expecting more M&A activity in 2020 compared to 2019, according to a new outlook from KPMG. 

New medical treatments such as gene therapies come with a high price tag up to six figures, and drugmakers are working hard to ensure they can get reimbursed for these medicines in creative ways.

Global venture capital funding in digital health dropped 6% in 2019, with 615 deals nabbing $8.9 billion in capital.